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AbstrACt
Objectives To assess whether medication beliefs differ 
between women who use or not use medication for their 
somatic chronic diseases during pregnancy and whether 
this association varies across diseases.
Design Cross- sectional web- based survey.
setting Multinational study in Europe.
Participants Pregnant women or women with children 
less than 1 year old from European countries and with 
asthma, allergy, cardiovascular, rheumatic diseases, 
diabetes, epilepsy and/or inflammatory bowel diseases 
(IBD).
Primary and secondary outcome measure Differences 
in scores of the Beliefs about Medicines Questionnaire 
(BMQ).
results In total, 1219 women were included (ranging 
from 736 for allergy to 49 for IBD). Women using 
medication for their chronic disease (n=770; 63%) had 
higher scores on the BMQ subscales necessity (16.6 vs 
12.1, p<0.001) and benefits (16.2 vs 15.4, p<0.001), and 
lower values on the subscales overuse (12.5 vs 13.1; 
p=0.005) and harm (9.8 vs 10.7, p<0.001) than women 
not using medication. No significant differences were 
shown for the concerns subscale (12.5 vs 12.3, p=0.484). 
Beliefs varied somewhat across diseases but in general 
more positive beliefs among women using medication 
were shown. Epilepsy was the disease where less 
differences were observed between women using and not 
using medication.
Conclusion Women’s beliefs were associated with 
medication use during pregnancy with only small 
differences across the diseases. Knowing pregnant 
women’s beliefs could help identify women who are 
reluctant to use medication and could guide counselling to 
support making well- informed treatment decisions.
IntrODuCtIOn
Worldwide, the number of women using 
over- the- counter or prescribed medication 
during pregnancy has been estimated to 
be 80%–90%.1 2 Although many prescribed 
medications during pregnancy are for 
pregnancy- related symptoms, a substantial 
number of prescriptions are also to treat 
chronic diseases.3 However, adherence to 
chronic medication during pregnancy is low. 
Previous studies among pregnant women with 
various chronic diseases (eg, asthma, epilepsy 
and inflammatory bowel diseases) have 
shown that about 40% of these women do 
not adequately adhere to their medication,4 5 
which challenges appropriate management 
of the underlying maternal disease.6 Subop-
timally treated maternal chronic diseases 
like epilepsy, asthma, diabetes and mental 
disorders can have a negative impact on the 
mother and on the unborn child (eg, low 
birth weight, macrosomia, preterm birth or 
perinatal mortality).7–11 So, adequate medi-
cation use is essential for both maternal and 
child health.
There are several theoretical models that 
can be used to explain and improve behaviours 
such as medication taking. An example is 
the health belief model in which beliefs are 
associated with behaviours.12 Previous studies 
have shown that patients’ medication beliefs 
are an important factor that can influence 
treatment adherence.5 13–15 These beliefs and 
their association with adherence may differ 
across diseases.16 Women generally perceive 
strengths and limitations of this study
 ► This study is the first comparing medication beliefs 
among women using or not using medication during 
pregnancy for various chronic diseases.
 ► Over 1000 women from several European countries 
were included in the study.
 ► Diseases and medication in this study are based on 
self- reported data and the recruitment method can-
not discard selection bias.
copyright.











pen: first published as 10.1136/bm





2 Roldan Munoz S, et al. BMJ Open 2020;10:e034529. doi:10.1136/bmjopen-2019-034529
Open access 
medication use during pregnancy as potentially harmful 
for the unborn child, even for medications that have 
been proven to be safe.4 17–19 A newly published litera-
ture review concluded that women were more reluctant 
to use medication during pregnancy and that they tend 
to overestimate the teratogenic risk of medications. The 
perceived risk is influenced by different factors including 
the type of medication.5 Currently, little is known about 
pregnant women’s medication beliefs and its association 
with medication use during pregnancy.
The primary aim of this study was to assess whether 
medication beliefs differ between women who use medi-
cation (medicated women) during pregnancy for their 
somatic chronic diseases (ie, allergy, asthma, cardiovas-
cular diseases, rheumatic diseases, diabetes, epilepsy and 
inflammatory bowel diseases) and those who do not use 
such medication (non- medicated women) during preg-
nancy. The secondary aim was to assess whether differ-
ences in beliefs between medicated and non- medicated 
women vary depending on the disease.
PArtICIPAnts AnD methODs
Participants
This is a substudy of the ‘Multinational Medication Use 
in Pregnancy Study’, a cross- sectional, multinational web- 
based survey study performed in 18 countries in Europe, 
America and Australia. The study has been described in 
details elsewhere.2 In short, pregnant women at any gesta-
tional week and mothers with a child less than 1 year of 
age were asked via banners on national websites or social 
media networks frequently visited by pregnant women 
and new mothers to complete an anonymous online 
questionnaire ( www. questback. com). This questionnaire 
was accessible between 1 October 2011 and 29 February 
2012. The questionnaire contained a variety of ques-
tions including demographics (ie, region of residence, 
age, marital status, working status, educational level, 
smoking status before pregnancy and immigrant status), 
and pregnancy- related questions (ie, maternal status of 
pregnancy, previous children, use of folic acid during 
the pregnancy, smoking status and alcohol intake during 
pregnancy and whether the pregnancy was planned or 
not). The full questionnaire and the list of websites and 
social networks used in each country have been published 
previously.2
In this substudy, women from any European country 
who had at least one somatic chronic disease were 
included. Women were asked to indicate which chronic 
diseases they had from a list of diseases: asthma, allergy, 
rheumatic diseases (including rheumatic arthritis and 
psoriatic arthritis), diabetes (type I or II), epilepsy and 
cardiovascular diseases (including high cholesterol, hyper-
tension and heart disease). In addition, the responders 
could indicate any ‘other chronic disease’. Responses 
provided in this free- text entry field were screened by one 
of the researchers (AL) and where relevant recoded as 
one of the diseases of the list. Deep vein thrombosis and 
thrombophilia were included as cardiovascular diseases. 
Also, one additional chronic disease was created based 
on the open- ended response, that is, inflammatory bowel 
diseases, consisting of ulcerative colitis and Crohn’s 
disease.
For each chronic disease, women were asked if they 
were currently using medication and if so, if they could 
report the medication they use in a free- text entry field. 
All recorded medications were classified according to the 
WHO Anatomical Therapeutic Chemical code.20 Iron 
preparations, vitamins and minerals were excluded.
The responders were additionally asked the following 
question: ‘Do you have any other comments about your 
medication use during pregnancy?’ The answer to this 
entry allowed women to further describe their beliefs and 
perceptions regarding the use of medication during preg-
nancy. The answers were translated into English and the 
transcripts were screened to identify general themes by 
one of the authors (SRM) and discussed with a second 
author (HN).
Patient and public involvement
Patients or public were not directly involved in this study.
Outcome variable
The outcome variable used in this study was pregnant 
women’s medication beliefs, which were assessed using 
the Beliefs about Medicines Questionnaire (BMQ).21–23 The 
BMQ was developed by Horne et al and contains questions 
about beliefs about medication in general and about specific 
medication. The BMQ- General consists of three subscales, 
that is, overuse, harm and benefits with four items each. The 
BMQ- Specific consists of two subscales, that is, necessity of 
taking the prescribed medication and concerns about the 
potential adverse consequences of taking the medication. 
Both scales consist of five items. Each item of the BMQ 
has to be answered on a 5- point Likert scale, ranging from 
‘strongly disagree=1’ to ‘strongly agree=5’. Therefore, the 
sum scores of the subscales overuse, harm and benefits range 
from 4 to 20 and the sum scores of the subscales necessity 
and concerns range from 5 to 25, with higher scores repre-
senting stronger beliefs of each subscale.
The survey was translated into the official language of 
the participating countries. Validated versions of the trans-
lated BMQ- General and BMQ- Specific subscales were used 
when they were available.22 24–29 Otherwise, translation 
from English and back translations were executed by two 
independent translators. For all BMQ subscales, missing 
values were imputed using the estimation- maximisation 
algorithm if a respondent had no more than two missing 
items on the subscale (ie, ≥50% completion in the overuse, 
harm and benefits subscales; ≥60% completion in the neces-
sity and concerns subscales).30 If more than two items were 
missing, the respondent was excluded. BMQ values were 
ultimately imputed for 68 women, 5.6% of the study 
population.
Internal consistency was measured calculating Cron-
bach’s alpha for each BMQ subscale per chronic disease. 
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Figure 1 Flow chart of the included population. BMQ, Beliefs about Medicines Questionnaire.
The lowest and the highest values of Cronbach’s alpha 
were 0.58 (epilepsy) and 0.79 (rheumatic diseases) for 
overuse; 0.62 (epilepsy) and 0.78 (allergy) for harm; 0.66 
(epilepsy) and 0.82 (asthma) for benefits; 0.63 (epilepsy) 
and 0.85 (diabetes) for concerns; and 0.90 (for all diseases) 
for necessity.
Besides the subscales, the necessity minus concerns differ-
ential (necessity − concerns) was calculated. A positive differ-
ential indicates that the benefits of using medication 
outweigh the concerns whereas the concerns weigh higher 
in case of a negative differential.31
statistical analyses
Differences between medicated and non- medicated 
women in their characteristics were analysed using Pear-
son’s χ2 tests or Fisher’s exact tests. T- tests were used to 
assess differences between medicated and non- medicated 
women for all included diseases together and per disease 
in the different BMQ subscales (ie, overuse, harm, benefits, 
necessity and concerns) and the necessity − concerns differ-
ential. In these tests, the included study sample was 
corrected by survey weight adjustment for age and educa-
tion level using the reference values from Eurostat.32 
In the weighting procedure, each woman was assigned 
a weighting factor based on the population proportion 
per country divided by the sample proportion in each 
age- by- education stratum per country. Women under- 
represented in our sample were assigned a weight greater 
than 1, while those over- represented received a weight 
smaller than 1.33 The survey weight for the entire study 
sample had a mean of 0.93 (range 0.13–5.05). We addi-
tionally performed sensitivity analyses in which the t- tests 
were conducted using the non- weighted study sample. 
There is discussion in the literature about the use of para-
metric tests for Likert scales.34 Therefore, we additionally 
examined differences in BMQ subscales between medi-
cated and non- medicated women non- parametrically 
using Wilcoxon- Mann- Whitney tests.
P values <0.05 were considered statistically signifi-
cant. The statistical analyses were conducted using Stata 
V.14 (StataCorp, College Station, TX) and figures were 
created in Microsoft Excel 2010 (Microsoft, Redmond, 
WA, USA).
results
In total, 1219 out of 9483 (12.9%) women reported a 
somatic chronic disorder and were included in this study. 
The most prevalent disease was allergy (n=736, 60%), 
followed by asthma (n=413, 34%), cardiovascular disease 
(n=238, 20%), rheumatic disease (n=118, 10%), diabetes 
(n=51, 4.2%), epilepsy (n=50, 4.1%) and inflammatory 
bowel disease (n=49, 4.0%) (figure 1).
The women were on average 30 years old (SD: 5.2, 
range: 16–52) and about half of the women (52%) were 
pregnant at the time of completing the survey (table 1).
About two- thirds of the women reported the use of 
at least one medication to treat their somatic chronic 
diseases during pregnancy (n=770, 63%). This ranges 
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Region of residence, n (%) 0.051
  Northern Europe* 552 (45) 349 (45) 203 (46)
  Western Europe† 298 (24) 248 (32) 121 (27)
  Eastern Europe‡ 369 (30) 173 (22) 125 (28)
Maternal age       0.039
  Mean, SD 30.1, 5.2 30.4, 5.1 29.5, 5.4
  Range min- max 16–52 16–52 17–50
Currently pregnant       0.630
  Yes 630 (52) 402 (52) 228 (51)
  No 589 (48) 368 (48) 221 (49)
Previous children       <0.001
  Yes 600 (49) 424 (55) 195 (43)
  No 619 (51) 346 (45) 254 (57)
Marital status       0.001
  Married or cohabiting 1141 (94) 734 (95) 407 (91)
  Divorced/single or others 78 (6) 36 (5) 42 (9)
Folic acid use§       0.239
  Yes 1102 (91) 704 (92) 398 (90)
  No 105 (9) 61 (8) 44 (10)
Working status       0.002
  Student 116 (10) 59 (8) 57 (13)
  Home maker 95 (8) 68 (9) 27 (6)
  Healthcare personnel (ie, physician) 177 (15) 125 (16) 52 (12)
  Employed in another sector 712 (58) 452 (59) 260 (58)
  Job seeker 52 (4) 27 (4) 25 (6)
  None of the above 66 (5) 38 (5) 28 (6)
Educational level       0.637
  Primary school 66 (5) 38 (5) 28 (6)
  High school 338 (28) 216 (28) 122 (27)
  University or college 672 (55) 421 (55) 251 (56)
  Other education 143 (12) 95 (12) 48 (11)
Alcohol use after awareness of being pregnant 0.354
  No 189 (16) 641 (84) 383 (86)
  Yes 1024 (84) 125 (16) 64 (14)
Smoking before pregnancy 0.014
  No 786 (65) 516 (67) 270 (60)
  Yes 432 (35) 253 (33) 179 (40)
Smoking during pregnancy 0.631
  No 1105 (91) 700 (91) 405 (90)
  Yes 113 (9) 69 (9) 44 (10)
Planned pregnancy       0.495
  No 108 (9) 65 (8) 43 (10)
  Yes 1108 (91) 703 (92) 404 (90)
Continued
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Immigrant status¶       0.138
  No 1176 (97) 748 (97) 428 (96)
  Yes 42 (3) 22 (3) 20 (5)
Numbers may not add up to total due to missing values. Minor missing value is 0.08% and major missing value is 1.31%. Missing values: 
maternal age n=16, folic acid use n=12, working status n=1, alcohol use after awareness of being pregnant n=6 (cannot remember what is 
considered as missing n=5), smoking before pregnancy n=1, smoking during pregnancy n=1, planned pregnancy n=4, immigrant status n=1.
Statistically significant results (ie, p<0.05) are presented in bold.
Examined chronic diseases include: allergy, asthma, cardiovascular diseases, rheumatic diseases, diabetes, epilepsy and inflammatory bowel 
diseases.
*Northern Europe includes Finland (13%), Iceland (1.3%), Norway (19%) and Sweden (12%).
†Western Europe includes Austria (0.9%), France (4.2%), Italy (7.1%), Netherlands (1.7%), Switzerland (6.2%) and UK (10%).
‡Eastern Europe includes Croatia (2.6%), Poland (6.9%), Russia (11%), Serbia (1.8%) and Slovenia (1.7%).
§Indicates folic acid use before and/or during pregnancy.
¶Women having the first language different from the official main language in the country of residency.
Table 1 Continued
from 56% of women using medication for rheumatic 
diseases to 90% of women using medication for diabetes 
(figure 1). The most commonly reported medications 
were piperazine derivatives (R06AE) for allergy, selec-
tive beta-2- adrenoreceptor agonists (R03AC) for asthma, 
methyldopa (C02AB) for cardiovascular diseases, gluco-
corticoids (H02AB) for rheumatic diseases, fast- acting 
insulin (A10AB) for diabetes, other antiepileptic drugs 
(N03AX) for epilepsy, and aminosalicylic acid and similar 
agents (A07EC) for inflammatory bowel diseases.
Some patient characteristics differed significantly 
between the medicated and non- medicated women. 
Medicated women were on average older (30.4 vs 29.5 
years, p=0.039), more often had previous children (55% 
vs 43%, p<0.001), were more often married or cohabiting 
(95% vs 91%, p<0.001) and were less often smokers before 
knowing about their pregnancy (33% vs 40%, p=0.014). 
In addition, there were differences in the working status 
between the medicated and non- medicated women 
(p=0.002) (table 1).
There were 359 women out of the 1219 who provided 
an open- ended answer to the question ‘Do you have any 
other comments about your medication use during preg-
nancy?’ From those answers, five themes were identified, 
that is, confident, underinformed, confused, guilt and 
avoiding medication. In all themes, there were women 
from the medicated and non- medicated groups. Exam-
ples of statements supporting these themes are presented 
in table 2.
beliefs about medicines
In general, medicated women had more positive beliefs 
than non- medicated women. Statistically significant 
differences between the weighted mean scores of the 
medicated and non- medicated women were shown in 
the overuse, harm, benefits and necessity subscales, but not 
concerns subscale. Mean scores of the medicated group 
were lower than those of the non- medicated group for 
overuse (12.5 vs 13.1, respectively, p=0.005) and harm 
(9.8 vs 10.7, respectively, p<0.001) and higher for benefits 
(16.2 vs 15.4, p<0.001) and necessity (16.6 vs 12.1, p<0.001, 
respectively). There was no difference on the concerns 
subscale between medicated and non- medicated women 
(12.5 vs 12.3, p=0.484) (figure 2A). For each disease, 
statistically significant differences between medicated 
and non- medicated women were shown in at least two 
of the subscales except for epilepsy where no statistically 
significant differences between medicated and non- 
medicated women were shown for any of the subscales 
(figure 2B–H).
The necessity − concerns differential was positive for all 
chronic diseases together in the medicated group but it 
was negative for the non- medicated group. This means 
that medicated women perceived that the benefits of 
taking prescribed medication outweigh their risks. The 
mean difference of the necessity − concerns differential 
varied across the somatic diseases for medicated and non- 
medicated women. In the medicated groups, the differen-
tial was positive for each of the chronic diseases. Women 
with diabetes had the highest beliefs that the benefits 
of using medication for their chronic disease outweigh 
the risks (+9.0), while women with rheumatic diseases 
had the lowest beliefs in a positive benefit- risk balance 
(+3.3). For the non- medicated group, the differential for 
each chronic disease was close to zero, with the highest 
differential for diabetes (+1.6) and the lowest differen-
tial for cardiovascular diseases (−0.6). The differential 
was statistically significantly higher for medicated than 
for non- medicated women across all examined chronic 
disease groups except for pregnant women with epilepsy 
(figure 3).
The sensitivity analyses in which no survey weight 
adjustment was used showed similar results to the analyses 
with survey weight adjustment (see online supplemen-
tary materials e- Figure 1 and e- Figure 2). The additional 
analyses assessing the association between medicated and 
non- medicated women and the BMQ subscales using a 
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Table 2 Identified themes and examples of statements provided by the responders regarding medication use during 
pregnancy
Confident ’I have been to the specialist and I have received good information and support.’
(Medicated woman with inflammatory bowel disease, 30 years old from Norway)
’People told me things about amoxicillin that my doctor gave me, but he told me that it is not harmful 
and that I needed it. Listen to your doctor and trust him.’
(Medicated woman with rheumatic disease, 43 years old from Croatia)
‘I cannot say that I restricted myself. I used medications as it was needed, I do not think it caused any 
harm to my child.’
(Non- medicated woman with cardiovascular disease, 23 years old from Russia)
Underinformed ‘Which medicines are proven harmless to the foetus, percentages, thank you! Many are afraid to take 
any medicines during pregnancy because of an exact answer may not be.’
(Non- medicated woman with cardiovascular disease, 26 years old from Finland)
‘It is very difficult to find a drug that is acceptable in pregnancy. Even for very simple things it is stated 
that pregnancy is a contraindication.’
(Non- medicated woman with cardiovascular disease, 26 years old from Russia)
‘I chose to use medication minimally due to uncertain information about how this could affect the 
foetus.’
(Non- medicated woman with cardiovascular disease, 26 years old from Norway)
Confused ‘Frequently we see differences in drugs information and in recommendations from our general doctors 
or gynaecologists. Should we believe the drug information or to the other side?’
(Medicated woman with asthma and allergy, 31 years old from Croatia)
’I find it hard to be in the middle of opinions from doctors, between the gynaecologist and the medical 
specialist.
One says I can take all my medication, while the gynaecologist said that everything must be stopped. 
Who to believe?’
(Medicated woman with inflammatory bowel disease and rheumatic disease, 26 years old from 
Switzerland)
‘To me it seems like that there is a kind of psychological terror on the use of medications. To some 
doctors, no medication can be taken during pregnancy, others give far too many possibilities in this 
regard.’
(Medicated woman with rheumatic disease, 39 years old from Italy)
Guilt ‘In a previous pregnancy, I used Panadol every day to painful knee ache, so that I was able to walk. 
So my son was born with a multicystic kidney and an undescended testicle. I think that the drug could 
have an impact on birth defect.’
(Non- medicated woman with inflammatory bowel disease, 24 years old from Finland)
‘Unfortunately, I had to take many medications and I felt very guilty (and I still do feel guilty) but if I did 
not take them, my child would probably not be born.’
(Medicated woman with cardiovascular disease, 37 years old from Italy)
‘I've reduced after consultation with the neurologist the dosage, as I had concerns for the child. It 
came to seizures because the level was too low, so the dose had to be increased again. Despite my 
concerns, I had to take the medication. It was very difficult for me, but I had no choice.’
(Medicated woman with epilepsy, 30 years old from Switzerland)
Avoiding medication ‘I stopped taking my medication as soon as I knew I was pregnant.’
(Medicated woman with rheumatic disease, 27 years old from Switzerland)
‘Generally: I'm terrified to hurt my foetus and try to avoid all drugs, both with and without a 
prescription. I have sleeping problems, but do not take the pill the doctor has prescribed to me (for the 
same reason). But daily life becomes heavy when you cannot sleep.’
(Non- medicated woman with rheumatic disease, 36 years old from Norway)
‘I intentionally did not take medications during pregnancy.’
(Non- medicated woman with asthma and allergy, 26 years all from Russia)
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Figure 2 Beliefs about Medicines Questionnaire (BMQ) weighted mean score with 95% CIs for (A) each BMQ subscale 
for all chronic diseases and for (B- H) each chronic disease by use of medication. The BMQ- Specific and BMQ- General are 
copyrighted (Professor Robert Horne).
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Figure 3 Beliefs about Medicines Questionnaire (BMQ) weighted necessity − concerns differential for all chronic diseases and 
for each chronic disease by use of medication. Values higher than 1 indicate that the necessity of the medications is larger than 
the concerns. The BMQ- Specific and BMQ- General are copyrighted (Professor Robert Horne).
non- parametric approach showed similar results (see 
online supplementary materials e- Table 1).
DIsCussIOn
In our study, more than a third of the responding women 
did not use medication for their chronic disease during 
pregnancy. These women had more negative beliefs than 
the two- thirds of women who used or continued to use 
medication during pregnancy. This difference was shown 
across different chronic diseases with the exception of 
epilepsy. For epilepsy, medicated and non- medicated 
pregnant women had similar medication beliefs.
The proportion of women using medication for their 
somatic chronic disease varied widely across the diseases 
in our study (from 56% for rheumatic diseases to 90% for 
diabetes). This variation in medication use during preg-
nancy is in line with previous studies showing percentages 
ranging from 62% for the treatment of chronic psychiatric 
disorders35 to 93% for the treatment of hypothyroidism.36 
Another study showed that patient characteristics such 
as educational level and occupation influence pregnant 
women’s perceived risks of medication use.5 We also 
observed some differences in sociodemographic charac-
teristics between medicated and non- medicated women, 
such as maternal age, marital status or having previous 
children. Further studies should asses the role of these 
factors in the association between beliefs and the decision 
to use medication.
Previous studies in pregnant women have shown 
that positive medication beliefs are associated with 
higher medication use and better treatment adher-
ence.31 35 36 Our study supports this association from a 
broader medication- taking perspective, and adds to this 
knowledge that the differences in beliefs between medi-
cated and non- medicated pregnant women were shown 
across various diseases, except for epilepsy. For epilepsy, 
medicated and non- medicated women had similar beliefs 
with particularly high concerns beliefs. Previous studies 
have shown that more than 50% of epileptic women would 
discontinue their medication during pregnancy.37 38 It is 
long understood that some antiepileptics (ie, valproic 
acid and phenytoin) are teratogenic and more recent 
findings also indicate neurodevelopmental risks to the 
offspring.39 This may explain the similarity in concerns 
about medication among medicated and non- medicated 
women with epilepsy.
The provided comments to the free- text entry outline 
the lack of information among patients and healthcare 
professionals on the adequate use of medication during 
pregnancy. This is highly relevant since knowledge is 
a prerequisite for the appropriate use of a treatment 
among pregnant women. However, information about 
medication use during pregnancy is often lacking. A 
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previous study showed, for instance, that 90% of the 
reviewed summary of product characteristics (SmPC) 
were restricting the use of medication during pregnancy 
but that SmPCs often do not provide a clear rationale for 
this restricted use. More specifically, 89% of those SmPCs 
did not specify whether or not the medication crossed 
the placenta and in 67% of the SmPCs it was just stated 
that clinical experience data were not available.40 More-
over, SmPCs do not provide alternative solutions. There-
fore, the various healthcare professionals involved in the 
treatment of pregnant women (eg, general practitioners, 
specialists treating their chronic diseases, pharmacists, 
midwives and gynaecologists) will have to rely on other, 
sometimes scarce or diverging information sources which 
could result in inconsistent advice to pregnant women. 
Therefore, more and clearer information about the use 
of medication during pregnancy is needed.
Not using medication for a chronic disease does not 
necessarily imply inappropriate behaviour of the preg-
nant women since the need of medication use depends 
on factors such as disease severity and other external 
factors (eg, for allergy, there is a low risk of events in 
certain seasons of the year). However, positive medica-
tion beliefs among women could contribute to the deci-
sion of continuing their medication during pregnancy. 
Therefore, patients’ beliefs should be discussed with the 
woman, and this information can be used to target those 
patients who are reluctant to continue with the required 
medication during pregnancy. Educational interventions 
have been successful in increasing appropriate medica-
tion use in pregnant and non- pregnant patients in various 
situations as well as on attenuating negative beliefs and 
enhancing positive beliefs.41–44 This could lead to better 
disease control. Innovative decision support tools that 
empower women and enable a shared decision- making 
approach about medications in pregnancy have been 
developed for some diseases45 and could lead to better 
informed treatment decisions. Further development of 
such tools, also for other diseases, should be the focus 
of the future. If a patient still decides not to continue a 
treatment during pregnancy, closer monitoring to the 
maternal and child health should be conducted.
strengths and limitations
To our knowledge, this is the first study in which medi-
cation beliefs are compared between pregnant women 
who use and who do not use medication for their somatic 
chronic disease. Moreover, we assessed these differences 
for various diseases in a large sample of women from 
several European countries.
Although a large number of women were included in 
this study, the numbers for some diseases are relatively 
low, particularly for those non- medicated, and the results 
per disease should therefore be interpreted cautiously.
Another limitation of this study is that the diseases and 
used medications are based on self- reporting without a 
medical confirmation. This implies that the accuracy 
of the data depended on the accuracy of the women. 
However, a previous study comparing self- reported and 
pharmacy records showed sufficient accuracy of self- 
reported medication use.46
It is known that survey responders have the tendency 
to respond relatively more neutral to Likert scale ques-
tions.47 Therefore, we have examined the distribution of 
the answers for each BMQ question for each disease in 
our study and we observed large variability in the distri-
butions (see online supplementary material e- Table 2.)
We used the BMQ to assess pregnant women’s beliefs 
about medication. However, also other beliefs could be 
relevant to assess in this population. Future research 
should develop validated measures of pregnancy- specific 
beliefs about prescribed and over- the- counter medicines, 
and use patient- centred approaches in the development 
of the items.
Furthermore, due to the recruitment method used in 
this study it was not possible to calculate response rates 
and selection bias cannot be discarded. The educational 
level in our sample was higher than in the average popu-
lation per country. To take this into account, we employed 
sample survey weights. The reference values used in this 
weighting represented women in reproductive age in 
each of the European countries32 but were not specific of 
the pregnant population.
COnClusIOn
In this multinational European study we found an asso-
ciation between women’s beliefs and medication use in 
pregnancy. Women with somatic chronic diseases using 
medication in pregnancy had more positive medication 
beliefs than those who did not use medication. This result 
was independent of the underlying disease, as the associa-
tion was shown in each disease except for epilepsy, where 
medicated and non- medicated women had similar medi-
cation beliefs. In addition, it was shown that women with 
chronic diseases lacked confidence, felt underinformed, 
confused, guilty about medication use and avoided them 
during pregnancy. Appropriate educational interventions 
and innovative decision support tools to assist tailored 
counselling and guidance before and during pregnancy 
are therefore warranted, and could lead to more positive 
beliefs, enhancing a well- informed decision about medi-
cation use during pregnancy.
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